Nikolaus B. Binder

Nikolaus B. Binder

Auto-generated profile, based on publicly available information

Nikolaus B. Binder

Deutsches Institut für Normung e.V. (DIN)

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NBNikolaus Binder
Nikolaus Binder
CMChristine Miller
Christine Miller
MYMasaki Yoshida
Masaki Yoshida
KIKazuki Inoue
Kazuki Inoue
SNShinichi Nakano
Shinichi Nakano
BZBaohong Zhao
Baohong Zhao
Inflammatory bone resorption mediated by osteoclasts is a major cause of morbidity and disability in many inflammatory disorders, including rheumatoid arthritis (RA). The mechanisms that regulate osteoclastogenesis and bone resorption in inflammatory settings are complex and have not been well elucidated. In this study, we identify the immunoregulator differentially expressed in FDCP 6 homolog (Def6) as a novel inhibitor of osteoclastogenesis in physiological and inflammatory conditions. Def6 deficiency in Def6−/− mice enhanced the sensitivity of osteoclast precursors to the physiological osteoclastogenic inducer receptor activator for NF-κB ligand, and Def6−/− osteoclasts formed actin rings. Furthermore, Def6 deficiency markedly increased TNF-α–induced osteoclastogenesis in vitro and in vivo and enhanced bone resorption in an inflammatory osteolysis mouse model. TNF-α serum levels correlated negatively with Def6 expression levels in osteoclast precursors obtained from RA patients, and the osteoclastogenic capacity of the osteoclast precursors was significantly inversely correlated with their Def6 expression levels, indicating that Def6 functions as an inhibitor of excessive osteoclast formation and bone destruction in RA. Mechanistically, Def6 suppressed osteoclastogenesis and the expression of key osteoclastogenic factors NFATc1, B lymphocyte–induced maturation protein-1, and c-Fos by regulating an endogenous IFN-β–mediated autocrine feedback loop. The Def6-dependent pathway may represent a novel therapeutic target to prevent pathological bone destruction.

Verified
Journal Article
Open access
PDF file
MLMartina Leitner
Martina Leitner
CBChristian Büchold
Christian Büchold
RPRalf Pasternack
Ralf Pasternack
NBNikolaus B. Binder
Nikolaus B. Binder
GMGary Moore
Gary Moore
Hereditary factor XIII (FXIII) deficiency is a rare autosomal bleeding disorder which can cause life-threatening bleeding. Acquired deficiency can be immune-mediated or due to increased consumption or reduced synthesis. The most commonly used screening test is insensitive, and widely used quantitative assays have analytical limitations. The present study sought to validate Technofluor FXIII Activity, the first isopeptidase-based assay available on a routine coagulation analyser, the Ceveron s100. Linearity was evidenced throughout the measuring range, with correlation coefficients of >0.99, and coefficients of variation for repeatability and reproducibility were <5% and <10%, respectively. A normally distributed reference range of 47.0–135.5 IU/dL was derived from 154 normal donors. Clinical samples with Technofluor FXIII Activity results between 0 and 167.0 IU/dL were assayed with Berichrom® FXIII Activity, a functional ammonia release assay, and the HemosIL™ FXIII antigen assay, generating correlations of 0.950 and 0.980, respectively. Experiments with a transglutaminase inhibitor showed that Technofluor FXIII Activity can detect inhibition of enzymatic activity. No interference was exhibited by high levels of haemolysis and lipaemia, and interference by bilirubin was evident at 18 mg/dL, a level commensurate with severe liver disease. Technofluor FXIII Activity is a rapid, accurate and precise assay suitable for routine diagnostic use with fewer interferents than ammonia release FXIII activity assays.

9 July 2025 in Expert Review of Hematology
Verified
Journal Article
Open access
FDFrançois yves louis Depasse
François yves louis Depasse
NBNikolaus B. Binder
Nikolaus B. Binder
MBMariona Bono
Mariona Bono
MGMatthias Germer
Matthias Germer
MHMichael Heins
Michael Heins
PTPeter Turecek
Peter Turecek
Von Willebrandfactor (VWF) plays a crucial role in hemostasis: its interactions with endothelialmatrices, platelets, and factor VIII make it a key player in both primaryhemostasis and coagulation. Pathology associated with VWF spans mild to severebleeding manifestations in the case of inherited von Willebrand disease (VWD),the most common congenital bleeding disorder, or acquired von Willebrandsyndrome (AVWS). Conversely, VWF can be associated with thromboticmanifestations in situations related to inflammation, infection, or inheritedor acquired ADAMTS13 defects. This reviewarticle aims to provide guidance on the use and interpretation of clinicallaboratory assays available to measure VWF and other factors related to VWD.Different VWF tests can be used in different clinical settings for efficientdiagnosis and patient management. Assay limitations are also addressed. A myriad oflaboratory assays, from first line to esoteric assays, exist to enable adequatediagnosis of VWD and other diseases influenced by VWF. Clinical investigationsof VWF are complicated because VWF has multiple functions which variably dependon the patient's pathophysiological status. The right choice of assays istherefore critical to provide adequate diagnosis in due time and withreasonable analytical efforts.

15 May 2020 in Analytical Biochemistry
Verified
Journal Article
Closed access
MLMartina Leitner
Martina Leitner
CBChristian Büchold
Christian Büchold
RPRalf Pasternack
Ralf Pasternack
NBNikolaus B. Binder
Nikolaus B. Binder

20 June 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ABAnnika Burger
Annika Burger
JSJan-Dirk Studt
Jan-Dirk Studt
AMAdriana Mendez
Adriana Mendez
LALorenzo Alberio
Lorenzo Alberio
PFPierre Fontana
Pierre Fontana
Michael NaglerMichael Nagler
Michael Nagler
A universal calibrator for the determination of all anti-Xa inhibitors would support laboratory processes. We aimed to test the clinical performance of an anti-Xa assay utilizing a universal edoxaban calibrator to determine clinically relevant concentrations of all anti-Xa inhibitors. Following a pilot study, we enrolled 553 consecutive patients taking rivaroxaban, edoxaban, or apixaban from nine study centers in a prospective cross-sectional study. The Technochrom® anti-Xa assay was conducted using the Technoview® edoxaban calibrator. Using ultra-high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS), anti-Xa inhibitor drug concentrations were determined. Sensitivities and specificities to detect three clinically relevant drug concentrations (30 µgL−1, 50 µgL−1, 100 µgL−1) were determined. Overall, 300 patients treated with rivaroxaban, 221 with apixaban, and 32 with edoxaban were included. The overall correlation coefficient (rs) was 0.95 (95% CI 0.94, 0.96). An area under the receiver operating characteristic curve of 0.96 for 30 µgL−1, 0.98 for 50 µgL−1, and 0.99 for 100 µgL−1 was found. The sensitivities were 92.3% (95% CI 89.2, 94.6), 92.7% (89.4, 95.1), and 94.8% (91.1, 97.0), respectively (specificities 82.2%, 93.7%, and 94.4%). In conclusion, the clinical performance of a universal, edoxaban-calibrated anti-Xa assay was solid and most drug concentrations were predicted correctly.

4 July 2025 in Expert Review of Hematology
Verified
Journal Article
Open access
JPJürgen Patzke
Jürgen Patzke
NBNikolaus B Binder
Nikolaus B Binder
MBMariona Bono
Mariona Bono
FDFrançois yves louis Depasse
François yves louis Depasse
MGMatthias Germer
Matthias Germer
PTPeter Turecek
Peter Turecek
Von Willebrand factor (VWF) is a large multimeric protein present in the blood. Its most important and best characterized function is to control bleeding in primary hemostasis, which is triggered by different biophysical mechanisms and protein-receptor interactions involving different domains of VWF. Many different diseases related to VWF, most importantly von Willebrand disease comprising different types and sub-types, require diagnosis, laboratory analysis of concentration, and function of VWF. As several different specific functions of VWF are physiologically relevant, several different assays are needed. The aim of this article is to provide a comprehensive overview of all relevant assays together with a description of how each assay is technically designed. Furthermore, guidance is given for choosing the right and validated assay methods. This information includes technical requirements, analytical performance data, references to relevant guidelines and other guidance documents, and reference standards. Also, information on availability and the type of the assay is provided, such as automated or manual, in vitro diagnostics or research use only. Relation to the clinical use of these assays, as well as performance, and result interpretation is covered in a second article in the same issue of this journal by the same authors.